Jan Mous


Jan Mous, former CSO of Lion Bioscience, has been appointed CEO of genomic-based target discovery firm IntegraGen. Mous will also serve as chairman of the company’s board of directors. Mous left his post as CSO of Lion in January, after holding the position for three years. Prior to that, he spent fifteen years at Roche (Basel, Switzerland), where he was global head of genomics technology and managing director of the genetics/genomics technology platform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.